UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 254

Sortiert nach

Festschrift: of mice and myths: challenges and opportunities of capturing contemporary science in museums

Science Museum Group journal, 2023-01, Vol.13 (13)

Boyle, Alison

2023

Volltextzugriff (PDF)

Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications

Clinical pharmacology and therapeutics, 2022-12, Vol.112 (6), p.1191-1200

2022

Volltextzugriff (PDF)

Curating the collider: using place to engage museum visitors with particle physics

Science Museum Group journal, 2023-01, Vol.2 (2)

2023

Volltextzugriff (PDF)

Theory and every thing: acquiring the office of Professor Stephen Hawking as a resource for history and museology

Science Museum Group journal, 2024-05 (21)

2024

Volltextzugriff (PDF)

“Banishing the atom pile bogy”: Exhibiting Britain's first nuclear reactor

Centaurus, 2019-02, Vol.61 (1-2), p.14-32

Boyle, Alison

2019

Volltextzugriff (PDF)

Modern physics in the museum

Journal of the history of collections, 2019-11, Vol.31 (3), p.487-502

Boyle, Alison

2019

Volltextzugriff (PDF)

Exploring Staff–Student Partnership in Curriculum Design

Education sciences, 2024-01, Vol.14 (1), p.61

2024

Volltextzugriff (PDF)

FRI-423 Early treatment of patients with indeterminate HBV viraemia does not improve retention in care and risks overtreating patients who may spontaneously clear HBsAg

Journal of hepatology, 2024-06, Vol.80, p.S783-S784

2024

Volltextzugriff (PDF)

THU-045 Medicines optimisation in patients admitted with hepatic encephalopathy in UK centres

Journal of hepatology, 2024-06, Vol.80, p.S636-S637

2024

Volltextzugriff (PDF)

Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine

Clinical pharmacokinetics, 2019-12, Vol.58 (12), p.1553-1565

2019

Volltextzugriff (PDF)

COVID‐19 treatment in patients with comorbidities: Awareness of drug‐drug interactions

British journal of clinical pharmacology, 2021-01, Vol.87 (1), p.212-213

2021

Volltextzugriff (PDF)

Drug interactions: a review of the unseen danger of experimental COVID-19 therapies

Journal of antimicrobial chemotherapy, 2020-12, Vol.75 (12), p.3417-3424

2020

Volltextzugriff (PDF)

THU-210 - Coadministration of hepatitis C direct-acting antivirals and enzyme-inducing antiepileptic drugs: real-world experience from a multi-centre case series

Journal of hepatology, 2023-06, Vol.78, p.S1202-S1202

2023

Volltextzugriff (PDF)

Coadministration of hepatitis C direct-acting antivirals and enzyme-inducing antiepileptic drugs: real-world experience from a multi-centre case series

Journal of hepatology, 2023-06, Vol.78, p.S1202

2023

Volltextzugriff (PDF)

Adverse events and clinical outcome associated with drotrecogin alfa-activated: A single-center experience of 498 patients over 8 years

Journal of critical care, 2012-06, Vol.27 (3), p.320.e7-320.e12

2012

Volltextzugriff (PDF)

Requests for drug-drug interaction data on direct-acting antivirals and enzyme inducing anti-epileptic agents: an overview of the HEP Interaction checker database of the University of Liverpool

Journal of hepatology, 2022-07, Vol.77, p.S580-S581

2022

Volltextzugriff (PDF)

Reasons for direct acting antiviral failure in patients referred for multi-disciplinary team discussion and virological outcomes of retreatment

Journal of hepatology, 2020-08, Vol.73, p.S361

2020

Volltextzugriff (PDF)

SAT080 - PPIs can be discontinued in over 60% of patients with cirrhosis: long term impact of screening for hepatitis C drug interactions

Journal of hepatology, 2020-08, Vol.73, p.S689-S689

2020

Volltextzugriff (PDF)

THU446 - Reasons for direct acting antiviral failure in patients referred for multi-disciplinary team discussion and virological outcomes of retreatment

Journal of hepatology, 2020-08, Vol.73, p.S361-S361

2020

Volltextzugriff (PDF)

PPIs can be discontinued in over 60% of patients with cirrhosis: long term impact of screening for hepatitis C drug interactions

Journal of hepatology, 2020-08, Vol.73, p.S689

2020

Volltextzugriff (PDF)

Fluvoxamine for the treatment of COVID-19

The Lancet global health, 2022-03, Vol.10 (3), p.e331-e331

2022

Volltextzugriff (PDF)

THU-156-Real world outcomes for Genotype 3 patients treated with glecaprevir/pibrentasvir: Real world outcomes from an unselected cohort

Journal of hepatology, 2019-04, Vol.70 (1), p.e230-e231

2019

Volltextzugriff (PDF)

THU-121-Real world outcomes from NS5a treatment failures undergoing therapy with sofosbuvir/velpatasvir/voxilaprevir and sofosbuvir/ glecaprevir/pibrentasvir

Journal of hepatology, 2019-04, Vol.70 (1), p.e212-e212

2019

Volltextzugriff (PDF)

FRI-251-Impact of hepatitis C treatment on patterns of drug use and subsequent treatment outcomes: High SVR rates despite increasing intravenous drug use in the post treatment period

Journal of hepatology, 2019-04, Vol.70 (1), p.e504-e505

2019

Volltextzugriff (PDF)

1 – 25 von 254

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(238)
Mit Volltextzugriff
(231)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(150)
Life Sciences & Biomedicine
(130)
Humans
(94)
Female
(55)
Male
(43)
General & Internal Medicine
(28)
Adult
(26)
Medicine, General & Internal
(24)
Pregnancy
(20)
Infant, Newborn
(19)
Child
(18)
Pediatrics
(18)
Risk Factors
(17)
Infant
(16)
Middle Aged
(15)
Adolescent
(14)
Animals
(14)
Child, Preschool
(14)
Multidisciplinary Sciences
(13)
Science & Technology - Other Topics
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Festschrift: of mice and myths: challenges and opportunities of capturing contemporary science in museums

Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications

Curating the collider: using place to engage museum visitors with particle physics

Holistic health and social care outreach for people experiencing homelessness with recent non-fatal overdose in Glasgow, Scotland: the Pharmacist and third sector Homeless charity worker Outreach Engagement Non-medical Independent prescriber Rx (PHOENIx) pilot randomised controlled trial

Theory and every thing: acquiring the office of Professor Stephen Hawking as a resource for history and museology

“Banishing the atom pile bogy”: Exhibiting Britain's first nuclear reactor

Modern physics in the museum

Exploring Staff–Student Partnership in Curriculum Design

FRI-423 Early treatment of patients with indeterminate HBV viraemia does not improve retention in care and risks overtreating patients who may spontaneously clear HBsAg

THU-045 Medicines optimisation in patients admitted with hepatic encephalopathy in UK centres

Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine

COVID‐19 treatment in patients with comorbidities: Awareness of drug‐drug interactions

Drug interactions: a review of the unseen danger of experimental COVID-19 therapies

THU-210 - Coadministration of hepatitis C direct-acting antivirals and enzyme-inducing antiepileptic drugs: real-world experience from a multi-centre case series

Coadministration of hepatitis C direct-acting antivirals and enzyme-inducing antiepileptic drugs: real-world experience from a multi-centre case series

Adverse events and clinical outcome associated with drotrecogin alfa-activated: A single-center experience of 498 patients over 8 years

Requests for drug-drug interaction data on direct-acting antivirals and enzyme inducing anti-epileptic agents: an overview of the HEP Interaction checker database of the University of Liverpool

Reasons for direct acting antiviral failure in patients referred for multi-disciplinary team discussion and virological outcomes of retreatment

SAT080 - PPIs can be discontinued in over 60% of patients with cirrhosis: long term impact of screening for hepatitis C drug interactions

THU446 - Reasons for direct acting antiviral failure in patients referred for multi-disciplinary team discussion and virological outcomes of retreatment

PPIs can be discontinued in over 60% of patients with cirrhosis: long term impact of screening for hepatitis C drug interactions

Fluvoxamine for the treatment of COVID-19

THU-156-Real world outcomes for Genotype 3 patients treated with glecaprevir/pibrentasvir: Real world outcomes from an unselected cohort

THU-121-Real world outcomes from NS5a treatment failures undergoing therapy with sofosbuvir/velpatasvir/voxilaprevir and sofosbuvir/ glecaprevir/pibrentasvir

FRI-251-Impact of hepatitis C treatment on patterns of drug use and subsequent treatment outcomes: High SVR rates despite increasing intravenous drug use in the post treatment period

Suchergebnisse filtern